Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT00028587
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00005831
- Locations
- 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States
S9912 Combination Chemo in Stage III Ovarian Cancer,
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 68
- Registration Number
- NCT00003896
- Locations
- 🇺🇸
Munson Medical Center, Traverse City, Michigan, United States
🇺🇸David C. Pratt Cancer Center at St. John's Mercy, St. Louis, Missouri, United States
🇺🇸Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 397
- Registration Number
- NCT00004054
- Locations
- 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00003065
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00005840
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 46
- Registration Number
- NCT00010257
- Locations
- 🇺🇸
HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, Minnesota, United States
🇺🇸Mount Nittany Medical Center, State College, Pennsylvania, United States
🇺🇸MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 722
- Registration Number
- NCT00028990
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸CentraCare Health Plaza, Saint Cloud, Minnesota, United States
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00014118
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00006027
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Community Hospital of Los Gatos, Los Gatos, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.